Compounded tirzepatide — July 2024

quinn_sf said:

The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

quinn_sf said:

The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

quinn_sf said:

The boring version of this is the one that works, and the boring version is: measure a baseline, change one variable, wait, measure again under the…

Thank you for spelling out the reasoning rather than just the conclusion.

Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

PharmHunterJen said:

If two explanations both fit, the useful question is which one predicts something the other does not.

Second this. Posting only so the count is not one.